Découvrez nos professeurs et professeures!

Revenir au répertoire
Fiche précédente
Fiche suivante

Paul Toren

Médecin clinicien enseignant sous octroi agrégé

Paul Toren
paul.toren.1@ulaval.ca
Centre de recherche sur le cancer
Centre de recherche du CHU de Québec - Université Laval
Partager la fiche :

Contribution à la recherche

Axe de recherche de l'Université Laval :

Santé et bien-être durables

Thématiques de recherche de la Faculté de médecine :

Oncologie

Domaines et intérêts de recherche du (de la) professeur(e) :

Cancer
  • Cancer la prostate
  • Cancer de l'appareil urinaire
  • Cancers hormonaux-dépendants
  • Interaction hôte - tumeur

Projets de recherche

  • Targeting sex steroids to improve the response to bladder cancer immunotherapy - Instituts de recherche en santé du Canada - Subvention Projet, chercheur principal - 2021-10-01 au 2026-09-30
  • Repurposing bicalutamide to improve the response to immune checkpoint inhibition for treatment of advanced urothelial carcinoma - Société de recherche sur le cancer - UpCycle 2.1, co-chercheur - 2022-08-01 au 2026-07-31
  • Exploiter les interactions endocriniennes-immunes pour améliorer le traitement des cancers urologiques - Fonds de recherche du Québec - Santé - Chercheurs-boursiers cliniciens - Juniors 1 et 2, Seniors, chercheur principal - 2022-07-01 au 2024-06-30
  • Food and Drug Regulations_CUASF Bladder Cancer Canada Terms of Reference 2022 - Association canadienne d'urologie, chercheur principal - 2022-08-02 au 2023-08-01
  • A study of macrophages as predictors of prostate cancer radiotherapy response - Association canadienne d'urologie, chercheur principal - 2022-01-26 au 2023-01-25
  • Development of next-generation biomarkers for prostate cancer treatment - Ministère de la Santé et des Services sociaux, Fondation Canadienne pour l'innovation (La) - Fonds des leaders John-R.-Evans (FLJR), chercheur principal - 2019-07-01 au 2021-12-31
  • (FRSQ 91289) Androgen-receptor dependent changes in human bladder cancer macrophages.” - Northeastern Section of the American Urological Association, chercheur principal - 2019-09-04 au 2021-09-03
  • Sex steroids as modulators of the prostate cancer immune microenvironment - Société de recherche sur le cancer - Subvention de fonctionnement, chercheur principal - 2018-09-01 au 2021-08-31

Publications

  • Effects of omega-3 fatty acids supplementation on perioperative blood loss and complications after radical prostatectomy, Samuel Fradet, Jean-François Pelletier, Narcisse Singbo, Louis Lacombe, Paul Toren, Michele Lodde, Thierry Dujardin, Rabi Tiguert, Yves Fradet, Karine Robitaille, Vincent Fradet, Clinical Nutrition ESPEN, 2022, 10.1016/j.clnesp.2021.12.011
  • Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer, Samuel Tremblay, Lily Summers-Trasiewicz, Frédéric Pouliot, Juanita M. Crook, Keyue Ding, Laurence Klotz, Paul Toren, Journal of Urology, 2021, 10.1097/JU.0000000000001946
  • Reply by Authors, Samuel Tremblay, Lily Summers-Trasiewicz, Frédéric Pouliot, Juanita M. Crook, Keyue Ding, Laurence Klotz, Paul Toren, Journal of Urology, 2021, 10.1097/JU.0000000000001946.03
  • Switching Cancers: A Systematic Review Assessing the Role of Androgen Suppressive Therapy in Bladder Cancer, Kassim Kourbanhoussen, Catherine McMartin, Michele Lodde, Alexandre Zlotta, Richard T. Bryan, Paul Toren, European Urology Focus, 2021, 10.1016/j.euf.2020.10.002
  • Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival, Paul Toren, Hervé Brisson, David Simonyan, Hélène Hovington, Louis Lacombe, Alain Bergeron, Yves Fradet, World Journal of Urology, 2021, 10.1007/s00345-020-03358-x
  • Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?, Catherine McMartin, Louis Lacombe, Vincent Fradet, Yves Fradet, Michele Lodde, Paul Toren, Clinical Genitourinary Cancer, 2019, 10.1016/j.clgc.2019.07.016
  • Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients, France‐Hélène Joncas, Fabrice Lucien, Mélanie Rouleau, Fannie Morin, Hon Sing Leong, Frédéric Pouliot, Yves Fradet, Caroline Gilbert, Paul Toren, The Prostate, 2019, 10.1002/pros.23901
  • Switching from a GnRH agonist to a GnRH antagonist in prostate cancer patients: A systematic review and meta-analysis, Kaleem S. Atchia, Christopher J.D. Wallis, Neil Fleshner, Paul Toren, Canadian Urological Association Journal, 2019, 10.5489/cuaj.5996
  • Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial, Paul Toren, Azik Hoffman, Keyue Ding, France-Hélène Joncas, Véronique Turcotte, Patrick Caron, Frédéric Pouliot, Yves Fradet, Éric Lévesque, Chantal Guillemette, Laurence Klotz, Clinical Cancer Research, 2018, 10.1158/1078-0432.CCR-18-1187
  • Contemporary outcomes of palliative transurethral resection of the prostate in patients with locally advanced prostate cancer, Joanie Pelletier, Sarah-Jeanne Cyr, Anne-Sophie Julien, Yves Fradet, Louis Lacombe, Paul Toren, Urologic Oncology: Seminars and Original Investigations, 2018, 10.1016/j.urolonc.2018.05.004
  • Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors, Vincent Fradet, Paul Toren, Molière Nguile-Makao, Michele Lodde, Jérome Lévesque, Caroline Léger, André Caron, Alain Bergeron, Tal Ben-Zvi, Louis Lacombe, Frédéric Pouliot, Rabi Tiguert, Thierry Dujardin, Yves Fradet, BJU International, 2018, 10.1111/bju.14041
  • Sex steroids in the tumor microenvironment and prostate cancer progression, Clovis Boibessot, Paul Toren, Endocrine-Related Cancer, 2018, 10.1530/erc-17-0493
  • 2017 NSAUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4896
  • Analysis of the translatome in solid tumors using polyribosome profiling/RNA-Seq, Pauline Adjibade, Valerie Grenier St-Sauveur, Arnaud Droit, Edouard W. Khandjian, Paul Toren, Rachid Mazroui, Journal of Biological Methods, 2016, 10.14440/jbm.2016.151
  • Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer, Paul Toren, Soojin Kim, Fraser Johnson, Amina Zoubeidi, PLOS ONE, 2016, 10.1371/journal.pone.0152861
  • MP62-06 COMBINED AKT AND MEK PATHWAY BLOCKADE IN PRE-CLINICAL MODELS OF ENZALUTAMIDE-RESISTANT PROSTATE CANCER, Paul Toren, Soojin Kim, Amina Zoubeidi, The Journal of Urology, 2016, 10.1016/j.juro.2016.02.914
  • PD32-01 PRE-CLINICAL RATIONALE FOR COMBINATION PI3K AND BRD4 INHIBITION IN ADVANCED PROSTATE CANCER, Paul Toren, Jared Allman, Soojin Kim, Amina Zoubeidi, The Journal of Urology, 2016, 10.1016/j.juro.2016.02.677
  • Pre-clinical rationale for combination PI3K and BRD4 inhibition in advanced prostate cancer., Paul Toren, Amina Zoubeidi, Jared Allman, Journal of Clinical Oncology, 2016, 10.1200/jco.2016.34.2_suppl.234
  • Podium Session 1: Prostate Cancer June 26, 2016 1050–1150., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2016
  • Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models., Toren P, Kim S, Cordonnier T, Crafter C, Davies BR, Fazli L, Gleave ME, Zoubeidi A, European urology, 2015, 10.1016/j.eururo.2014.08.006
  • Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT., Klotz L, O'Callaghan C, Ding K, Toren P, Dearnaley D, Higano CS, Horwitz E, Malone S, Goldenberg L, Gospodarowicz M, Crook JM, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, 10.1200/jco.2014.58.2973
  • 2015 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2015
  • Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer., Toren PJ, Kim S, Pham S, Mangalji A, Adomat H, Guns ES, Zoubeidi A, Moore W, Gleave ME, Molecular cancer therapeutics, 2015, 10.1158/1535-7163.mct-14-0521
  • Active surveillance in patients with a PSA >10 ng/mL, Paul Toren, Lih-Ming Wong, Narhari Timilshina, Shabbir Alibhai, John Trachtenberg, Neil Fleshner, Antonio Finelli, Canadian Urological Association Journal, 2014, 10.5489/cuaj.2121
  • Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer., Zardan A, Nip KM, Thaper D, Toren P, Vahid S, Beraldi E, Fazli L, Lamoureux F, Gust KM, Cox ME, Bishop JL, Zoubeidi A, Oncogenesis, 2014, 10.1038/oncsis.2014.30
  • Targeting the PI3K/Akt pathway in prostate cancer: Challenges and opportunities (Review), PAUL TOREN, AMINA ZOUBEIDI, International Journal of Oncology, 2014, 10.3892/ijo.2014.2601
  • Periprostatic Adipose Tissue and Prostate Cancer Progression: New Insights into the Tumor Microenvironment, Paul Toren, Vasundara Venkateswaran, Clinical Genitourinary Cancer, 2014, 10.1016/j.clgc.2013.07.013
  • Novel non-AR therapeutic targets in castrate resistant prostate cancer., Toren PJ, Gleave ME, Translational andrology and urology, 2013, 10.3978/j.issn.2223-4683.2013.09.09
  • Reply, Paul Toren, Antonio Finelli, Urology, 2013, 10.1016/j.urology.2013.04.056
  • Results of a national population-based study of outcomes of surgery for renal tumors associated with inferior vena cava thrombus., Toren P, Abouassaly R, Timilshina N, Kulkarni G, Alibhai S, Finelli A, Urology, 2013, 10.1016/j.urology.2013.04.054
  • Rational cotargeting of Pim-1 and Akt in prostate cancer, Paul Toren, Amina Zoubeidi, Expert Review of Anticancer Therapy, 2013, 10.1586/14737140.2013.816461
  • Catastrophic sepsis and hemorrhage following transrectal ultrasound guided prostate biopsies, Paul Toren, Roshan Razik, John Trachtenberg, Canadian Urological Association Journal, 2013, 10.5489/cuaj.785
  • Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study., Toren P, Margel D, Kulkarni G, Finelli A, Zlotta A, Fleshner N, BMJ (Clinical research ed.), 2013, 10.1136/bmj.f2109
  • Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer, Paul J Toren, Martin E Gleave, Asian Journal of Andrology, 2013, 10.1038/aja.2013.38
  • Re: Shilo Y, Zisman A, Lindner A, et al. The predominance of benign histology in small testicular masses. Urol Oncol 2012;30:719-22., Toren P, Lo K, Urologic oncology, 2013, 10.1016/j.urolonc.2012.11.018
  • Use of a novel parenchymal clamp for laparoscopic and open partial nephrectomy, Paul Toren, Turki Al-Essawi, Anthony Mclean, Umesh Jain, Canadian Urological Association Journal, 2013, 10.5489/cuaj.936
  • Diet, Obesity, and Cancer Progression: Are Adipocytes the Link?, Paul Toren, Benjamin C. Mora, Vasundara Venkateswaran, Lipid Insights, 2013, 10.4137/lpi.s10871
  • Exercise effects on adipokines and the IGF axis in men with prostate cancer treated with androgen deprivation: A randomized study., Santa Mina D, Connor MK, Alibhai SM, Toren P, Guglietti C, Matthew AG, Trachtenberg J, Ritvo P, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2013, 10.5489/cuaj.235
  • Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care?, Klotz L, Toren P, Current oncology (Toronto, Ont.), 2012, 10.3747/co.19.1298
  • 2012 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012
  • 236 EXPERIENCE WITH RECTOURETHRAL FISTULA REPAIR AND DESCRIPTION OF A NOVEL SURGICAL TECHNIQUE, Ashley Cox, Paul Toren, Sender Herschorn, The Journal of Urology, 2012, 10.1016/j.juro.2012.02.291
  • Point-of-care clinical documentation: assessment of a bladder cancer informatics tool (eCancerCareBladder): a randomized controlled study of efficacy, efficiency and user friendliness compared with standard electronic medical records., Bostrom PJ, Toren PJ, Xi H, Chow R, Truong T, Liu J, Lane K, Legere L, Chagpar A, Zlotta AR, Finelli A, Fleshner NE, Grober ED, Jewett MA, Journal of the American Medical Informatics Association : JAMIA, 2011, 10.1136/amiajnl-2011-000221
  • Use of a novel parenchymal clamp for laparoscopic and open partial nephrectomy., Toren P, Al-Essawi T, McLean A, Jain U, Canadian Urological Association Journal, 2010
  • 2010 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2010
  • Small incidentally discovered testicular masses in infertile men--is active surveillance the new standard of care?, Toren PJ, Roberts M, Lecker I, Grober ED, Jarvi K, Lo KC, The Journal of urology, 2010, 10.1016/j.juro.2009.12.012
  • Catastrophic sepsis and hemorrhage following transrectal ultrasound guided prostate biopsies., Toren P, Razik R, Trachtenberg J, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2010
  • The effect of nerve-sparing surgery on patient-reported continence post-radical prostatectomy., Toren P, Alibhai SM, Matthew A, Nesbitt M, Kalnin R, Fleshner N, Trachtenberg J, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • Comparison of epidural and intravenous patient controlled analgesia in patients undergoing radical cystectomy., Toren P, Ladak S, Ma C, McCluskey S, Fleshner N, The Canadian journal of urology, 2009
  • 2009 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • Canadian Urological Association, 63rd Annual Meeting, Edmonton, AB, June 22-25, 2008., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2008
  • The patient presenting with genitourinary AIDS, Paul Toren, Wendy Wobeser, Supportive Care for the Urology Patient, 2005, 10.1093/acprof:oso/9780198529415.003.0017
  • Is 24-hour urinary calcium a surrogate marker for dietary calcium intake?, Toren PJ, Norman RW, Urology, 2005, 10.1016/j.urology.2004.10.025
  • CYCLOPHOSPHAMIDE INDUCED HEMORRHAGIC CYSTITIS SUCCESSFULLY TREATED WITH PENTOSANPOLYSULPHATE, PAUL J. TOREN, RICHARD W. NORMAN, The Journal of Urology, 2005, 10.1097/01.ju.0000146626.78180.83

Contribution à l'enseignement aux cycles supérieurs

Étudiant(e)s dirigé(e)s*

Depuis 2009
  • Samuel Tremblay - Maîtrise avec mémoire - En cours
  • Zohra Berrehail - Doctorat - En cours
  • Geneviève Trépanier - Maîtrise avec mémoire - En cours

Encadrement d'étudiant(e)s pour les programmes suivants :

Disponibilité d'encadrement d'étudiant(e)s

Ce (cette) professeur(e) est présentement à la recherche d'étudiant(e)s.

Envoyer un courriel
*Les supervisions d’étudiant(e)s de 1er cycle en stage de recherche et de résident(e)s aux études médicales postdoctorales seront répertoriées ultérieurement.
Mettre à jour mon profil de professeur(e)